

## Referencer til kliniske retningslinjer

### Hovedreferencer:

- Sundhedsstyrelsen (2018). Model for udarbejdelse af nationale kliniske retningslinjer. <https://www.sst.dk/-/media/Opgaver/Patientforl%C3%B8b-og-kvalitet/NKR/Metodehandbogen-2018.ashx?la=da&hash=22215410A43275099250C21574EB5787F2106857>
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.0 (updated July 2019). Cochrane, 2019. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- Aromataris E, Munn Z (Editors). *Joanna Briggs Institute Reviewer's Manual*. The Joanna Briggs Institute, 2017. Available from <https://reviewersmanual.joannabriggs.org/>
- Fra Forskning til Praksis. 2017. Munksgaard. Preben Ulrich Pedersen, Merete Bjerrum, Sasja Jul Håkonsen, Palle Larsen
- Schünemann 2013; Schünemann H, Brożek J, Guyatt G, Oxman A (editors). The GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. <https://gdt.grade.pro.org/app/handbook/handbook.html>
- Guyatt, G., Vist, G., Falck-Ytter, Y., Kunz, R., Magrini, N., and Schunemann, H. An emerging consensus on grading recommendations?. *ACP J Club*. 2006; 144: A8–A9
- <http://www.acpjc.org/Content/pdf/ACPJC-2006-144-1-A08.pdf>
- Guyatt, G.H., Oxman, A.D., Kunz, R., Jaeschke, R., Helfand, M., Liberati, A. et al. Incorporating considerations of resources use into grading recommendations. *BMJ*. 2008; 336: 1170–1173 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394579/pdf/bmj-336-7654-analysis-01170.pdf>
- Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008; 336: 924–926 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2335261/pdf/bmj-336-7650-analysis-00924.pdf>
- Guyatt, G.H., Oxman, A.D., Kunz, R., Vist, G.E., Falck-Ytter, Y., and Schunemann, H.J. What is “quality of evidence” and why is it important to clinicians?. *BMJ*. 2008; 336: 995–998 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364804/pdf/bmj-336-7651-analysis-00995.pdf>
- Guyatt GH et al. (2011). GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. *Journal of Clinical Epidemiology*. 64: 383-94. Guyatt GH et al. (2011). GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epi*. 6: 395-400. [https://www.jclinepi.com/article/S0895-4356\(10\)00330-6/pdf](https://www.jclinepi.com/article/S0895-4356(10)00330-6/pdf)
- Balshem H et al. (2011). GRADE guidelines: 3. Rating the quality of evidence. 64: 401-406: Guyatt GH et al. (2011). GRADE guidelines: 4. Rating the quality of evidence – study limitations (risk of bias). 64: 407-415.

[https://www.jclinepi.com/article/S0895-4356\(10\)00332-X/pdf](https://www.jclinepi.com/article/S0895-4356(10)00332-X/pdf)

- Guyatt, G.H., Oxman, A.D., Kunz, R., Falck-Ytter, Y., Vist, G.E., Liberati, A. et al. Going from evidence to recommendations. *BMJ*. 2008; 336: 1049–1051

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376019/pdf/bmj-336-7652-analysis-01049.pdf>

- Schunemann, H.J., Oxman, A.D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G.E. et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ*. 2008; 336: 1106–1110

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386626/pdf/bmj-336-7653-analysis-01106.pdf>

- GRADE Working Group. Systems for grading the quality of evidence and the strength of recommendations II: Pilot study of a new system. *BMC Health Serv Res*. 2005; 5: 25

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1084246/pdf/1472-6963-5-25.pdf>

#### Supplerende referencer:

- Moher D, Liberati A, Tetzlaff J, Altman D, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Medicine* 2009; 6: e1000097.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707599/pdf/pmed.1000097.pdf>

- Chandler J, Hopewell S. Cochrane methods – twenty years experience in developing systematic review methods. *Systematic Reviews* 2013; 2: 76

<https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/2046-4053-2-76>

#### PICO

- Guyatt GH et al. (2011). GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epi*. 6: 395-400.

[https://www.jclinepi.com/article/S0895-4356\(10\)00331-8/pdf](https://www.jclinepi.com/article/S0895-4356(10)00331-8/pdf)

- Anderson L, Petticrew M, Rehfuss E, Armstrong R, Ueffing E, Baker P, Francis D, Tugwell P. Using logic models to capture complexity in systematic reviews. *Research Synthesis Methods* 2011; 2: 33–42.

<https://onlinelibrary.wiley.com/doi/abs/10.1002/jrsm.32>

- Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. *Annals of Internal Medicine* 1997; 127: 380–387.

<https://annals.org/aim/article-abstract/710790/formulating-questions-locating-primary-studies-inclusion-systematic-reviews>

#### Litteratursøgning:

- Atkinson KM, Koenka AC, Sanchez CE, Moshontz H, Cooper H. Reporting standards for literature searches and report inclusion criteria: making research syntheses more transparent and easy to replicate. *Research Synthesis Methods* 2015; **6**: 87-95.  
<https://onlinelibrary.wiley.com/doi/full/10.1002/jrsm.1127>
- Bai Y, Gao J, Zou D, Li Z. Is MEDLINE alone enough for a meta-analysis? *Alimentary Pharmacology and Therapeutics* 2007; **26**: 125-126; author reply 126.  
<https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2036.2007.03339.x>
- Baudard M, Yavchitz A, Ravaud P, Perrodeau E, Boutron I. Impact of searching clinical trial registries in systematic reviews of pharmaceutical treatments: methodological systematic review and reanalysis of meta-analyses. *BMJ* 2017; **356**: j448.  
<https://www.bmj.com/content/356/bmj.j448>
- Bennett DA, Jull A. FDA: untapped source of unpublished trials. *Lancet* 2003; **361**: 1402-1403.  
<https://europepmc.org/article/med/12727389>
- Briscoe S. A review of the reporting of web searching to identify studies for Cochrane systematic reviews. *Research Synthesis Methods* 2018; **9**: 89-99.  
<https://onlinelibrary.wiley.com/doi/abs/10.1002/jrsm.1275>

#### Kritisk vurdering:

- Brouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L for the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. *Can Med Assoc J.* 2010.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001530/pdf/182e839.pdf>
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019; **366**: l4898  
<https://www.bmj.com/content/366/bmj.l4898.long>
- Clark L, Fairhurst C, Torgerson DJ. Allocation concealment in randomised controlled trials: are we getting better? *BMJ* 2016; **355**: i5663.  
<https://www.bmj.com/content/355/bmj.i5663.long>
- Corbett MS, Higgins JPT, Woolacott NF. Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. *Research Synthesis Methods* 2014; **5**: 79-85.  
<https://onlinelibrary.wiley.com/doi/abs/10.1002/jrsm.1090>

- Fergusson D, Aaron SD, Guyatt G, Hebert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. *BMJ* 2002; **325**: 652-654.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1124168/pdf/652.pdf>
- Gravel J, Opatrny L, Shapiro S. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say? *Clinical Trials (London, England)* 2007; **4**: 350-356.  
(Ikke open access)
- Haahr MT, Hróbjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. *Clinical Trials (London, England)* 2006; **3**: 360-365.  
(Ikke open access)

### Metanalyser

- Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Research Synthesis Methods* 2010; **1**: 97-111.  
<https://onlinelibrary.wiley.com/doi/abs/10.1002/jrsm.12>
- Borenstein M, Higgins JPT. Meta-analysis and subgroups. *Prev Sci* 2013; **14**: 134-143.  
(Ikke open access)
- Konstantopoulos S. Fixed effects and variance components estimation in three-level meta-analysis. *Research Synthesis Methods* 2011; **2**: 61-76.  
<https://onlinelibrary.wiley.com/doi/10.1002/jrsm.35>
- López-López JA, Page MJ, Lipsey MW, Higgins JPT. Dealing with multiplicity of effect sizes in systematic reviews and meta-analyses. *Research Synthesis Methods* 2018; **9**: 336-351.  
<https://onlinelibrary.wiley.com/doi/abs/10.1002/jrsm.1310>
- Mavridis D, Salanti G. A practical introduction to multivariate meta-analysis. *Statistical Methods in Medical Research* 2013; **22**: 133-158.  
<https://journals.sagepub.com/doi/abs/10.1177/0962280211432219>